Education Use Only
For educational use only — Not for clinical decision-making without independent verification
Medical Associates  ·  Department of Nephrology ← urinenephrology.org
Nephrology Education Series

Ecoli Pathotypes Treatment Guide

Andrew Bland, MD, FACP, FAAP UICOMP · UDPA · Butler COM 2025-01-01 20 min read

E. COLI PATHOTYPES: COMPREHENSIVE CLASSIFICATION & TREATMENT GUIDE

Clinical Reference for Physicians


TABLE 1: E. COLI PATHOTYPES - CLASSIFICATION & ANTIBIOTIC TREATMENT

Abbreviation Full Name Primary Disease(s) Key Clinical Features Antibiotic Treatment Treatment Rationale
STEC / EHEC Shiga Toxin-Producing E. coli / Enterohemorrhagic E. coli Hemorrhagic colitis, Hemolytic Uremic Syndrome (HUS) Bloody diarrhea, severe abdominal cramps, minimal fever. Most common serotype: O157:H7 CONTRAINDICATED Antibiotics increase HUS risk 14-fold by triggering toxin release. NO clinical benefit.
ETEC Enterotoxigenic E. coli Traveler’s diarrhea, Watery diarrhea Profuse watery diarrhea, abdominal cramps, low-grade fever. Leading cause of traveler’s diarrhea. YES ✓ (Moderate-severe cases) Shortens illness by 24-36 hours. Azithromycin or rifaximin preferred.
EPEC Enteropathogenic E. coli Infantile diarrhea, Persistent diarrhea Watery diarrhea in children <2 years (developing countries). Causes attaching-effacing lesions. SELECTIVE ⚠️ Consider only if persistent >2 weeks or severe. Most cases self-limited.
EAEC Enteroaggregative E. coli Acute & chronic watery diarrhea, Traveler’s diarrhea Watery diarrhea (can be persistent), low-grade fever. “Stacked brick” appearance on microscopy. SELECTIVE ⚠️ Evidence limited. Treat if moderate-severe or persistent. Similar to ETEC.
EIEC Enteroinvasive E. coli Dysentery-like illness, Inflammatory colitis Bloody/mucoid diarrhea, fever, severe cramps. Closely related to Shigella. Invades colonic epithelium. YES ✓ (Severe cases) Shortens duration and reduces complications. Treat like Shigella.
DAEC Diffusely Adherent E. coli Watery diarrhea (questionable pathogenicity) Watery diarrhea in children. Pathogenic role unclear and debated. NO Insufficient evidence of pathogenicity. Supportive care only.
UPEC Uropathogenic E. coli Urinary tract infections (UTIs), Cystitis, Pyelonephritis Dysuria, frequency, urgency, flank pain, fever (if pyelonephritis). Most common cause of UTIs. YES Standard UTI treatment. Fluoroquinolones, TMP-SMX, nitrofurantoin, or fosfomycin.
NMEC Neonatal Meningitis E. coli Neonatal meningitis, Neonatal sepsis Fever, lethargy, poor feeding in neonates. Possesses K1 capsule enabling CNS invasion. YES Critical. Requires IV cephalosporins (cefotaxime) + aminoglycosides.
APEC Avian Pathogenic E. coli Avian colibacillosis (birds only) Respiratory disease, septicemia in poultry. Not typically a human pathogen. N/A Veterinary pathogen. Not relevant to human medicine.

TABLE 2: INTESTINAL vs. EXTRAINTESTINAL E. COLI

Category Pathotypes Included Primary Site General Approach
Intestinal Pathogenic E. coli (InPEC) STEC/EHEC, ETEC, EPEC, EAEC, EIEC, DAEC Gastrointestinal tract Variable - depends on specific pathotype
Extraintestinal Pathogenic E. coli (ExPEC) UPEC, NMEC, APEC Urinary tract, Blood, CNS, Respiratory (birds) Generally requires antibiotics

TABLE 3: ANTIBIOTIC TREATMENT DECISION TABLE

Pathotype Treat with Antibiotics? First-Line Agent(s) Dosing Key Pearl
STEC/EHEC NO - Contraindicated None - Supportive care + IV hydration N/A IV hydration within 4 days reduces HUS risk. Monitor for HUS up to 14 days.
ETEC YES - If moderate-severe Azithromycin (preferred) OR Rifaximin OR Ciprofloxacin Azithromycin 500mg x 3d; Rifaximin 200mg TID x 3d Drug of choice for traveler’s diarrhea. Shortens illness 24-36 hours.
EPEC MAYBE - If persistent >2 weeks Azithromycin OR TMP-SMX (children) Azithromycin 10 mg/kg/day x 3d; TMP-SMX 5 mg/kg BID x 5d Most cases self-limited. Common in developing countries.
EAEC MAYBE - If moderate-severe Azithromycin (same as ETEC) Azithromycin 500mg x 3d Clinical significance debated. Often co-detected with other pathogens.
EIEC YES - If severe Azithromycin OR Ceftriaxone Azithromycin 500mg x 3d; Ceftriaxone 1g IV daily Treat like Shigella - very similar organism.
DAEC NO None - Supportive care only N/A Pathogenicity questionable. Rarely detected clinically.
UPEC YES - Always Nitrofurantoin, Fosfomycin, TMP-SMX, Fluoroquinolones Varies by drug and severity (cystitis vs pyelonephritis) Uncomplicated cystitis: 3-5 days; Pyelonephritis: 7-14 days
NMEC YES - Critical emergency Cefotaxime + Gentamicin (IV) Cefotaxime 50 mg/kg Q8-12h + Gentamicin 2.5 mg/kg Q8-12h High mortality without treatment. Requires LP and blood cultures.

TABLE 4: VIRULENCE FACTORS BY PATHOTYPE

Pathotype Key Virulence Factor(s) Mechanism of Disease Diagnostic Marker
STEC/EHEC Shiga toxin (Stx1, Stx2), LEE pathogenicity island, Intimin (eae) Toxin inhibits protein synthesis → endothelial damage → HUS Stx1/Stx2 genes by PCR; Toxin assay
ETEC Heat-labile toxin (LT), Heat-stable toxin (ST), Colonization factors Toxins increase cAMP/cGMP → secretory diarrhea (cholera-like) LT/ST genes by PCR
EPEC Bundle-forming pilus (BFP), Intimin (eae gene), LEE pathogenicity island Attaching-effacing lesions → villous flattening → malabsorption eae + bfpA genes (typical EPEC); eae only (atypical EPEC)
EAEC Aggregative adherence fimbriae (AAF), AggR regulon, EAST toxin Forms biofilm on mucosa → persistent colonization and inflammation AggR gene or AAF genes by PCR
EIEC Invasion plasmid antigens (Ipa), Similar to Shigella virulence Invades colonic epithelium → inflammation, dysentery ipaH gene by PCR (similar to Shigella)
UPEC P fimbriae, Type 1 fimbriae, Hemolysin, CNF1 toxin Adhesion to uroepithelium → ascending infection → inflammation Culture from urine; No specific virulence testing needed
NMEC K1 capsule, IbeA protein, S fimbriae K1 capsule evades immune system → bacteremia → CNS invasion K1 antigen detection; CSF culture

TABLE 5: INFECTIOUS DOSE & TRANSMISSION ROUTES

Pathotype Infectious Dose (CFU) Primary Transmission Routes Incubation Period
STEC/EHEC Very low (10-100) Undercooked beef (especially ground), unpasteurized milk, contaminated water, petting zoos 1-8 days (median 3-4 days)
ETEC High (10⁶-10⁸) Contaminated food/water in developing countries, ice cubes, raw vegetables 12-72 hours
EPEC Moderate (10⁶) Contaminated food/water, person-to-person (daycare), fomites 12-48 hours
EAEC Unknown (likely moderate) Contaminated food/water, persistent environmental contamination Variable (1-8 days)
EIEC Low-moderate (10²-10⁴) Contaminated food/water, person-to-person fecal-oral, similar to Shigella 12-72 hours
UPEC N/A (ascending infection) Endogenous (from GI tract to urinary tract), sexual activity, catheterization Variable
NMEC N/A (vertical transmission) Maternal GI/vaginal colonization → neonatal infection during delivery 0-7 days of life

TABLE 6: GEOGRAPHIC & EPIDEMIOLOGIC PATTERNS

Pathotype Geographic Distribution Primary Age Groups Affected Special Populations at Risk
STEC/EHEC Primarily developed countries (North America, Europe, Japan) All ages, but HUS most common in children <5 and elderly >65 Children, elderly, immunocompromised
ETEC Worldwide; endemic in developing countries Adults (travelers from developed countries); Children in endemic areas International travelers, military personnel
EPEC Developing countries (Sub-Saharan Africa, Asia, Latin America) Infants and children <2 years Malnourished children, formula-fed infants
EAEC Worldwide distribution All ages HIV/AIDS patients (causes persistent diarrhea)
EIEC Developing countries; sporadic in developed countries All ages Travelers to endemic areas
UPEC Worldwide Women (reproductive age), Elderly men (prostatic disease) Diabetes, pregnancy, anatomic abnormalities, catheterized patients
NMEC Worldwide Neonates (especially <7 days) Premature infants, prolonged rupture of membranes

TABLE 7: LABORATORY DIAGNOSIS

Pathotype Traditional Methods Molecular Methods Rapid Tests Available Clinical Laboratory Availability
STEC/EHEC Culture on sorbitol-MacConkey agar (O157:H7 only) PCR for Stx1/Stx2 genes Shiga toxin EIA High - Most labs test for STEC
ETEC Not routinely cultured PCR for LT/ST genes Limited Low - Requires specialized molecular panels
EPEC Not routinely cultured PCR for eae, bfpA genes Limited Low - Requires molecular GI panels
EAEC Not routinely cultured PCR for AggR, AAF genes Limited Low - Requires molecular GI panels
EIEC Culture (lactose-negative on MacConkey) PCR for ipaH gene Limited Low - Often missed; similar to Shigella
UPEC Standard urine culture Not routinely needed Urine dipstick (leukocyte esterase, nitrites) High - Universally available
NMEC CSF culture, blood culture PCR for K1 capsule Blood culture (automated systems) High - Standard neonatal sepsis workup

Note: Multiplex molecular GI panels (e.g., BioFire FilmArray GI Panel, BD MAX Enteric panels) now available in many reference labs and can detect ETEC, EPEC, EAEC, EIEC, and STEC simultaneously.


TABLE 8: ANTIBIOTIC RESISTANCE PATTERNS (United States Data)

Pathotype High Resistance (>20%) Moderate Resistance (10-20%) Low Resistance (<10%) Universally Susceptible
ETEC Ampicillin (40-70%), Tetracycline (30-50%) TMP-SMX (10-30%), Fluoroquinolones (10-25%) Azithromycin (<5%) Carbapenems, Tigecycline
EPEC Ampicillin (50-70%), TMP-SMX (30-45%) Fluoroquinolones (5-15%), Cephalosporins (20-30%) Azithromycin (<5%) Carbapenems, Fosfomycin, Amikacin, Colistin
EAEC Ampicillin (60-70%), Tetracycline (30-40%) TMP-SMX (20-30%) Azithromycin (<10%) Carbapenems
EIEC Variable (similar to Shigella) Fluoroquinolones (regional variation) Azithromycin, Ceftriaxone Carbapenems
UPEC Ampicillin (40-50%), TMP-SMX (20-30% in some regions) Fluoroquinolones (10-30%), 1st gen cephalosporins Nitrofurantoin, Fosfomycin Carbapenems

ESBL-Producing E. coli: - Prevalence: 10-40% depending on region and healthcare vs. community-acquired - Affects: EPEC, EAEC, ETEC, UPEC - Confers resistance to: All penicillins, cephalosporins (except cefepime in some cases), monobactams - Remains susceptible to: Carbapenems, tigecycline, colistin (last resort)


CLINICAL DECISION ALGORITHMS

Algorithm 1: Acute Diarrhea After Well Water Exposure

Patient with diarrhea + well water exposure
                |
                ↓
        Is diarrhea bloody?
                |
        ┌───────┴───────┐
        |               |
       YES             NO
        |               |
        ↓               ↓
    STEC likely    Watery diarrhea
        |               |
        ↓               ↓
    Order:          Mild/self-limited?
    - Stool culture     |
    - Shiga toxin   ┌───┴───┐
                    |       |
    While pending: YES     NO
    - NO antibiotics |       |
    - NO antimotility ↓       ↓
    - IV hydration  Supportive  Moderate-severe?
    - Monitor HUS   care only   |
                                ↓
                            Consider antibiotics:
                            - Azithromycin 500mg x 3d
                            - IF STEC RULED OUT

Algorithm 2: Antibiotic Decision for Confirmed E. coli Pathotype

Confirmed E. coli pathotype identified
                |
                ↓
        Which pathotype?
                |
    ┌───────────┼───────────┐
    |           |           |
    ↓           ↓           ↓
  STEC/      ETEC/EAEC/   UPEC/
  EHEC        EIEC/EPEC    NMEC
    |           |           |
    ↓           ↓           ↓
   NO       Risk stratify  YES
Antibiotics      |       Antibiotics
    |            ↓       (Always)
    |     Severe/persistent/
    |     high-risk patient?
    |            |
    |      ┌─────┴─────┐
    |     YES         NO
    |      |           |
    |      ↓           ↓
    |   Antibiotics  Supportive
    |   indicated    care only
    |      |
    └──────┴──────────────────→ Treatment complete

CRITICAL TEACHING POINTS

1. The STEC Exception - NEVER FORGET

Why STEC is different: - ONLY E. coli pathotype where antibiotics are CONTRAINDICATED - Antibiotics increase HUS risk from baseline ~6% to ~56% (14-fold increase) - Mechanism: Antibiotics cause bacterial lysis → massive Shiga toxin release → endothelial damage - Even bacteriostatic antibiotics at sub-MIC concentrations increase toxin production

Mnemonic: “STEC = STOP antibiotics”

What DOES work for STEC: - Early IV hydration (within 4 days of symptom onset) - ONLY proven intervention - Close monitoring for HUS (daily CBC, BMP up to 14 days) - Avoid: Antibiotics, antimotility agents, NSAIDs

High-risk STEC features predicting HUS: - Age <5 years or >65 years - High initial WBC count (>15,000) - Stool culture positive early in illness - Stx2 (more virulent than Stx1) - Use of antibiotics


2. Geographic & Travel Considerations

ETEC - “Traveler’s Diarrhea” - Most common cause of traveler’s diarrhea (30-40% of cases) - Endemic in: Latin America, Africa, South Asia, Middle East - Classic scenario: Tourist develops watery diarrhea 2 days into Mexico trip - Prevention: “Boil it, cook it, peel it, or forget it” - Prophylaxis: Generally NOT recommended (promote resistance)

EPEC - “Infantile Diarrhea in Developing Countries” - After rotavirus, leading cause of death in children <2 in developing countries - Rare in developed countries - Important consideration in adopted children from endemic areas - Associated with malnutrition and formula feeding (lack of protective maternal antibodies)

STEC - “The Burger Bug” - Primarily developed countries (USA, Canada, UK, Japan, Germany) - Peak incidence: Summer months (BBQ season) - Outbreaks linked to: Ground beef, unpasteurized milk/juice, swimming pools, petting zoos - Cattle are asymptomatic reservoirs


3. Antibiotic Resistance - Emerging Threats

ESBL-Producing E. coli (20-40% of isolates in some areas): - Confers resistance to most β-lactams (including 3rd generation cephalosporins) - Most common gene: blaCTX-M (CTX-M-15 predominates) - Risk factors: Recent hospitalization, nursing home residence, recent antibiotic use, international travel - Treatment: Carbapenems (ertapenem, meropenem) for severe infections

Fluoroquinolone Resistance (Rising globally): - Campylobacter: 40% in some US regions, >80% in Southeast Asia - ETEC: 10-25% in travelers returning from Asia - Treatment failure rates: 15-30% with ciprofloxacin for traveler’s diarrhea - Alternative: Azithromycin (maintains low resistance <5%)

Why Azithromycin is increasingly preferred: - Low resistance across all diarrheagenic E. coli (<5%) - Safe in pregnancy and children - Once-daily dosing - Does NOT increase STEC toxin production (unlike fluoroquinolones) - Reduces fecal shedding (institutional benefit)


4. Not All E. coli Are Equal

Commensalism vs. Pathogenicity: - ~10⁸-10⁹ E. coli CFU/gram in normal stool - >99% of gut E. coli are BENEFICIAL or neutral - Produce vitamin K2, compete with pathogens, maintain gut homeostasis - Pathogenic E. coli require SPECIFIC virulence factors (toxins, adhesins, invasins)

Cannot distinguish by routine culture: - All E. coli grow on MacConkey agar as pink/red (lactose-fermenting) colonies - Exception: EHEC O157:H7 (sorbitol-negative) and EIEC (lactose-negative) - Requires molecular testing (PCR) or immunoassays to identify pathotypes - Many labs only test for STEC; other pathotypes require specific multiplex panels

Clinical implication: - Stool culture showing “normal flora including E. coli” does NOT rule out pathogenic E. coli - Must specifically order: STEC testing, GI pathogen panel, or send to reference lab


5. Special Populations - Different Rules Apply

Immunocompromised Patients (HIV, chemotherapy, transplant): - EAEC → persistent diarrhea (weeks to months), wasting - Higher risk of bacteremia with any InPEC pathotype - More likely to need antibiotics even for typically self-limited infections - Consider empiric treatment while awaiting cultures

Neonates (<28 days): - NMEC → life-threatening meningitis/sepsis - ANY E. coli bacteremia in neonate warrants LP (20-30% have concurrent meningitis) - Empiric coverage must include E. coli (ampicillin + gentamicin OR cefotaxime) - High mortality (15-40%) even with appropriate treatment

Pregnant Women: - UTIs (UPEC) progress to pyelonephritis more rapidly - Asymptomatic bacteriuria requires treatment (unlike non-pregnant women) - Increased risk of preterm labor with pyelonephritis - Antibiotic choices: Cephalexin, nitrofurantoin (avoid in 3rd trimester), fosfomycin - Avoid: Fluoroquinolones, TMP-SMX in 1st/3rd trimester

Elderly with Atherosclerosis: - Non-typhoidal Salmonella (and E. coli) can seed atherosclerotic plaques - Risk of mycotic aneurysm, endovascular infection - Lower threshold to treat Salmonella bacteremia in elderly - May require prolonged antibiotics (4-6 weeks)


6. Post-Infectious Complications - Think Beyond Acute Illness

Hemolytic Uremic Syndrome (HUS) - STEC: - Triad: Hemolytic anemia + Thrombocytopenia + Acute kidney injury - Occurs 5-10 days after diarrhea onset (as diarrhea resolving) - Most common cause of acute renal failure in children - 3-5% mortality, 12% develop ESRD, 25% have long-term renal sequelae - No specific treatment - supportive care, dialysis if needed - Avoid platelet transfusions unless life-threatening bleeding (may worsen thrombotic microangiopathy)

Reactive Arthritis (Reiter’s Syndrome): - Follows EIEC, Shigella, Salmonella, Campylobacter infections - Classic triad: Arthritis + Urethritis + Conjunctivitis (“Can’t see, can’t pee, can’t climb a tree”) - Strongly associated with HLA-B27 - Onset: 1-3 weeks after GI infection resolves - Treatment: NSAIDs, sometimes DMARDs if persistent

Guillain-Barré Syndrome (GBS): - Most commonly follows Campylobacter (but can follow other GI infections) - Molecular mimicry: Bacterial lipooligosaccharides cross-react with gangliosides in peripheral nerves - Onset: 1-3 weeks after infection - Ascending paralysis, areflexia, potential respiratory failure - Treatment: IVIG or plasmapheresis

Post-Infectious IBS (PI-IBS): - Develops in 10-15% of patients after acute bacterial gastroenteritis - Risk factors: Female sex, younger age, severity of acute illness, psychological stress - Symptoms persist >6 months after infection clears - Treatment: Standard IBS management (dietary, probiotics, antispasmodics)


7. Laboratory Pearls - Optimizing Diagnosis

When to order what:

Clinical Scenario Test to Order Rationale
Bloody diarrhea Stool culture + Shiga toxin assay (or STEC PCR) MUST rule out STEC before giving antibiotics
Watery diarrhea + fever Stool culture for Salmonella, Shigella, Campylobacter Standard bacterial pathogens
Traveler’s diarrhea Consider GI multiplex PCR panel Detects ETEC, EAEC, parasites; faster than culture
Persistent diarrhea (>7 days) GI multiplex panel + ova & parasites x3 EPEC, EAEC, Giardia, Cryptosporidium
HIV patient with chronic diarrhea Comprehensive testing: GI panel, O&P, mycobacterial culture, CMV Multiple opportunistic pathogens possible
Outbreak investigation Stool culture + save isolates for serotyping/PFGE Need isolates for epidemiologic analysis

Multiplex GI Panels (BioFire, Luminex, BD MAX): - Pros: Rapid (1-2 hours), detects multiple pathogens simultaneously, high sensitivity - Cons: Expensive ($200-400), may detect colonization vs. true infection, not all labs have - What they detect: STEC, ETEC, EPEC, EAEC, EIEC + Salmonella, Shigella, Campylobacter, viruses, parasites - Clinical use: Consider for severe illness, immunocompromised, outbreak, negative routine culture


8. Supportive Care - Never Forget the Basics

Hydration is the cornerstone: - Prevents dehydration-related mortality (especially children, elderly) - Oral rehydration solution (ORS) preferred if patient can tolerate PO - WHO ORS formula: Na+ 75 mEq/L, glucose 75 mmol/L (promotes Na-glucose cotransport) - IV fluids if: Severe dehydration, hemodynamic instability, intractable vomiting, altered mental status

What NOT to do: - Antimotility agents (loperamide, diphenoxylate) with bloody diarrhea or fever - Can precipitate toxic megacolon - Increase risk of HUS with STEC - Prolong illness with invasive pathogens (Shigella, EIEC) - Bismuth subsalicylate in children <12 years (Reye’s syndrome risk) - NSAIDs in suspected STEC (may worsen renal injury)

Nutrition: - Resume normal diet as soon as tolerated (including regular dairy if tolerated) - BRAT diet (bananas, rice, applesauce, toast) is outdated - insufficient calories/protein - Continue breastfeeding in infants - Small, frequent meals if nausea/cramping prominent

Probiotics: - Evidence mixed; generally safe - Possible benefit: Lactobacillus GG, Saccharomyces boulardii - Do NOT give if immunocompromised (risk of fungemia with S. boulardii)


9. Public Health & Reporting Requirements

Reportable Conditions (varies by state, but commonly include): - STEC/EHEC infection (ALL cases) - Hemolytic Uremic Syndrome - Shigellosis - Salmonellosis - Campylobacteriosis - Outbreaks (≥2 linked cases)

When to report: - Suspicion is sufficient - definitive diagnosis NOT required - Report to local/state health department within 24-48 hours - Helps identify outbreaks, contaminated food sources, common exposures - Health department may require follow-up stool cultures to clear food handlers

High-risk occupations requiring clearance: - Food handlers - Healthcare workers (direct patient care) - Daycare workers - Usually require 2 negative stool cultures ≥24 hours apart, ≥48 hours after antibiotic completion


10. Prevention Strategies - Patient Counseling

For patients with well water: - Annual testing for coliforms (minimum) - Test more frequently if: Nearby contamination, heavy rain/flooding, pregnant/infant in home - Shock chlorination after positive result - Consider UV treatment or filtration system - Safe distance: Well ≥50 feet from septic system, livestock

Food safety: - Cook ground beef to 160°F (71°C) - use meat thermometer - Avoid raw milk and raw milk products - Wash produce thoroughly, especially leafy greens - Separate cutting boards for raw meat and produce - Refrigerate promptly (<2 hours, <1 hour if >90°F)

Travel advice (ETEC prevention): - “Boil it, cook it, peel it, or forget it” - Avoid: Ice, tap water, raw vegetables, street food, buffets - Safe: Bottled water (sealed), hot coffee/tea, beer, wine, freshly cooked food - Consider taking azithromycin or rifaximin for self-treatment (not prophylaxis) - Prophylactic antibiotics NOT routinely recommended (promotes resistance)


SUMMARY: KEY DECISION POINTS

When Patient Has Diarrhea + Well Water Exposure:

1. Is it bloody diarrhea? - YES → Suspect STEC → DO NOT give antibiotics → Order Shiga toxin test + culture - NO → Continue evaluation

2. Is there fever or severe illness? - YES → Consider bacterial pathogen → Order stool culture - NO → Likely viral or mild bacterial → Supportive care

3. Is STEC ruled out (negative Shiga toxin + culture)? - YES → Can consider antibiotics if indicated by pathogen/severity - NO → Continue to withhold antibiotics

4. Which pathogen is identified? - Shigella → Give antibiotics (azithromycin) - Campylobacter → Risk stratify → Give if high-risk - Salmonella → Risk stratify → Usually no antibiotics unless high-risk - ETEC/EAEC/EIEC/EPEC → Assess severity → Consider antibiotics if moderate-severe

5. Patient is asymptomatic but worried about exposure? - NO prophylactic antibiotics - Education about symptoms to watch for - Reassurance that most exposures don’t cause illness


REFERENCES & RESOURCES

Key Guidelines: 1. IDSA 2017 Clinical Practice Guidelines for Infectious Diarrhea 2. CDC Guidelines for STEC Infections 3. WHO Guidelines for Diarrheal Disease Management

Useful Websites: - CDC E. coli Information: www.cdc.gov/ecoli - Travelers’ Health (Traveler’s Diarrhea): wwwnc.cdc.gov/travel - State Health Department Well Water Testing Resources

Continuing Education: - ID Board Review Courses (IDSA, Mayo Clinic) - CDC Laboratory Training Courses - APHL (Association of Public Health Laboratories) Resources


ACRONYMS & ABBREVIATIONS

  • AAF = Aggregative Adherence Fimbriae
  • APEC = Avian Pathogenic E. coli
  • BFP = Bundle-Forming Pilus
  • CFU = Colony Forming Units
  • DAEC = Diffusely Adherent E. coli
  • EAEC = Enteroaggregative E. coli
  • EHEC = Enterohemorrhagic E. coli
  • EIEC = Enteroinvasive E. coli
  • EPEC = Enteropathogenic E. coli
  • ESBL = Extended-Spectrum Beta-Lactamase
  • ETEC = Enterotoxigenic E. coli
  • ExPEC = Extraintestinal Pathogenic E. coli
  • GBS = Guillain-Barré Syndrome
  • HUS = Hemolytic Uremic Syndrome
  • InPEC = Intestinal Pathogenic E. coli
  • LEE = Locus of Enterocyte Effacement
  • LT = Heat-Labile Toxin
  • NMEC = Neonatal Meningitis E. coli
  • ORS = Oral Rehydration Solution
  • PI-IBS = Post-Infectious Irritable Bowel Syndrome
  • ST = Heat-Stable Toxin
  • STEC = Shiga Toxin-Producing E. coli
  • Stx = Shiga Toxin
  • TMP-SMX = Trimethoprim-Sulfamethoxazole
  • UPEC = Uropathogenic E. coli
  • UTI = Urinary Tract Infection

DOCUMENT INFORMATION

Created: 2025 Purpose: Physician reference for E. coli pathotype classification and treatment Based on: Iowa well water contamination exposure case discussion Evidence Level: Based on CDC guidelines, IDSA guidelines, and peer-reviewed literature Last Updated: October 2025


This document is intended for educational purposes for healthcare professionals. Clinical decisions should be individualized based on patient presentation, local epidemiology, and resistance patterns.